INmune Bio (NASDAQ:INMB – Get Free Report) had its price objective lowered by research analysts at Freedom Broker from $4.00 to $2.50 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Freedom Broker‘s price target points to a potential upside of 133.86% from the company’s previous close.
A number of other research analysts also recently weighed in on INMB. Wall Street Zen downgraded INmune Bio from a “hold” rating to a “sell” rating in a report on Saturday, November 7th. Weiss Ratings upgraded INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 19th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $2.50.
View Our Latest Stock Report on INMB
INmune Bio Stock Performance
Shares of NASDAQ:INMB traded up $0.02 during mid-day trading on Friday, hitting $1.07. The stock had a trading volume of 235,772 shares, compared to its average volume of 479,188. The company has a market cap of $33.10 million, a PE ratio of -1.77 and a beta of 0.97. INmune Bio has a 12-month low of $1.01 and a 12-month high of $2.60. The company’s 50 day moving average is $1.79 and its 200-day moving average is $1.62.
INmune Bio (NASDAQ:INMB – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02).
Hedge Funds Weigh In On INmune Bio
A number of hedge funds have recently modified their holdings of INMB. BlackRock Inc. acquired a new stake in INmune Bio during the second quarter valued at $508,000. Focus Partners Advisor Solutions LLC purchased a new position in INmune Bio in the second quarter valued at about $71,000. GSA Capital Partners LLP acquired a new position in INmune Bio in the 2nd quarter worth about $134,000. Bank of New York Mellon Corp acquired a new position in INmune Bio in the 2nd quarter worth about $35,000. Finally, Russell Investments Group Ltd. increased its position in INmune Bio by 64.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 25,246 shares of the company’s stock worth $49,000 after purchasing an additional 9,850 shares during the last quarter. 12.72% of the stock is owned by institutional investors and hedge funds.
INmune Bio Company Profile
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments that harness and modulate the innate immune system. The company’s research is aimed at addressing diseases in which chronic inflammation or impaired immune function plays a significant role, including cancer, neurodegenerative disorders and certain psychiatric conditions. Its lead product candidate is XPro, a next-generation tumor necrosis factor inhibitor designed to selectively neutralize soluble TNF while preserving transmembrane TNF signaling.
Further Reading
- Five stocks we like better than INmune Bio
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.
